The global burden of type 2 diabetes mellitus (T2DM) continues to escalate, prompting intensive research into novel therapeutic strategies beyond traditional oral hypoglycemics and insulin therapies. Among these, peptide based treatments have emerged as a highly promising avenue, particularly glucagon like peptide 1 (GLP1) analogues, which harness the physiological role of incretin hormones in glycemic regulation. GLP1 analogues exemplify the sophistication of peptide therapeutics in modern endocrinology by integrating metabolic control with ancillary benefits such as weight loss and cardiovascular protection.
GLP1 is a 30 amino acid peptide secreted by enteroendocrine L cells in the distal ileum and colon in response to nutrient intake. It plays a crucial role in the incretin effect, which is the augmentation of insulin secretion when glucose is ingested orally compared to intravenously. GLP1 enhances glucose dependent insulin release, inhibits glucagon secretion, delays gastric emptying, and promotes satiety through central mechanisms (Drucker, 2006).
Despite its therapeutic potential, native GLP1 has a very short half life of approximately one to two minutes, primarily due to rapid enzymatic degradation by dipeptidyl peptidase 4 (DPP4) and renal clearance. This pharmacokinetic limitation led to the development of synthetic GLP1 receptor agonists (GLP1 RAs), which are peptide analogues engineered to resist DPP4 cleavage and maintain systemic activity over a longer period.
GLP1 analogues are engineered through various molecular modifications to enhance stability, prolong half life, and optimize receptor interaction. Strategies include replacing the alanine residue at position 8 with another amino acid, such as glycine in liraglutide or aminoisobutyric acid in albiglutide, which makes the molecule resistant to DPP4 degradation. In other cases, lipidation techniques are used, as in liraglutide and semaglutide, allowing the analogue to bind reversibly to albumin and extend plasma circulation time. Some analogues, such as dulaglutide, are fused with the Fc portion of IgG4 to reduce renal clearance and decrease immunogenicity.
These molecular modifications enable GLP1 RAs to be administered less frequently. Instead of requiring daily injections, patients may receive them once or twice a week, improving adherence without compromising glycemic control.
GLP1 analogues are now established as a fundamental component in the treatment algorithm for T2DM, particularly in patients with obesity or cardiovascular comorbidities. Numerous randomized controlled trials have confirmed their superiority over traditional antidiabetic medications in achieving glycemic targets with a lower risk of hypoglycemia.
In addition, GLP1 RAs contribute to meaningful weight loss, which is a critical therapeutic goal in T2DM. They achieve this by delaying gastric emptying and suppressing appetite through central nervous system mechanisms. Semaglutide has demonstrated particularly strong outcomes, with average weight reductions exceeding 15 percent in non diabetic individuals with obesity in the STEP trials (Wilding et al., 2021).
The benefits are not limited to glycemic control and weight management. Cardiovascular outcome trials such as LEADER (liraglutide), SUSTAIN 6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE). These cardioprotective effects are thought to result from improvements in blood pressure, lipid profiles, and systemic inflammation (Marso et al., 2016).
The diverse effects of GLP1 analogues are due to the broad expression of GLP1 receptors in tissues including pancreatic islets, the central nervous system, cardiovascular tissues, and the gastrointestinal tract. Activation of the GLP1 receptor increases cyclic AMP production through G protein coupled signaling pathways, enhancing insulin gene transcription, stimulating beta cell proliferation, and reducing apoptosis (Campbell and Drucker, 2013).
In the central nervous system, particularly within the hypothalamus and brainstem, GLP1 RAs regulate appetite and food intake by modulating neuropeptide expression and neuronal excitability. Recent studies also indicate that GLP1 analogues may have neuroprotective and anti inflammatory effects, suggesting their potential in managing neurodegenerative complications of diabetes (Holst et al., 2011).
Despite their benefits, GLP1 analogues do have some limitations. Gastrointestinal side effects such as nausea and vomiting are common and may limit dose escalation, although these symptoms often diminish over time. Additionally, because most formulations require subcutaneous injection, some patients may find adherence challenging. However, oral formulations like semaglutide provide a convenient alternative (Davies et al., 2019).
Cost also represents a major barrier to widespread use, especially in low and middle income countries. Ongoing research aims to produce more cost effective analogues and develop advanced oral delivery systems. There is also growing interest in dual and triple receptor agonists that target multiple metabolic pathways, including glucose dependent insulinotropic peptide (GIP) and glucagon receptors.
Peptide therapeutics for T2DM are evolving rapidly. Agents such as tirzepatide, which activates both GIP and GLP1 receptors, have shown superior results in glycemic control and weight loss compared to GLP1 monotherapy (Jastreboff et al., 2022). These dual agonists represent a new generation of incretin based therapies.
Further advances include pegylation techniques, prodrug formulations, and depot based delivery systems to extend half life and provide steady plasma concentrations. There is also active investigation into how peptide therapies can synergize with interventions targeting the gut microbiome, epigenetic pathways, or beta cell regeneration.
GLP1 analogues represent a major advancement in the management of type 2 diabetes. They offer a holistic approach to metabolic disease by lowering blood glucose, supporting weight loss, and reducing cardiovascular risk. Their success illustrates the potential of peptide based therapeutics to address the complex challenges of chronic disease. With ongoing innovation in molecular design, drug delivery, and combination strategies, GLP1 analogues are poised to remain central in the evolving landscape of endocrinology.
Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders worldwide, characterized by progressive cognitive decline and memory impairment. Despite decades of research, therapeutic
Aging is a multifaceted biological process characterized by a progressive decline in physiological function and increased vulnerability to chronic diseases. At the cellular level, one
Aging is an intricate biological process characterized by the gradual decline in cellular and systemic functions, ultimately leading to increased susceptibility to diseases and mortality.
Mitochondrial-derived peptides (MDPs) have recently attracted significant interest for their multifaceted roles in cellular homeostasis, metabolism, and aging. Among these, MOTS-c (Mitochondrial Open Reading Frame
Copper peptides have long captured the attention of dermatologists and cosmetic chemists for their remarkable regenerative properties. Among them, GHK-Cu (glycyl-L-histidyl-L-lysine–copper) has emerged as a
